CSA Disarms Over 7,500 Fraudulent Investment Websites

Canadian securities regulators have announced the successful deactivation of over 7,500 fraudulent investment and crypto scam websites between June 2025 and February 2026. This initiative, highlighted during Fraud Prevention Month, aims to protect investors from online scams.

Health Canada Implements ICH Pharmaceutical Guidelines

Health Canada is implementing new International Council for Harmonisation (ICH) guidelines for pharmaceuticals, including M13A and Q12/Q14. These implemented ICH guidelines will take precedence over existing Health Canada guidance documents where discrepancies exist, potentially leading to amendments or withdrawals of current guidance.

ICH Consultations on Patient Preference, Extractables, and Adaptive Trials

Health Canada announced three International Council for Harmonisation (ICH) draft guidelines are open for public consultation. The consultations cover patient preference studies, extractables and leachables, and adaptive clinical trials, with comment deadlines ranging from November 2025 to April 2026.

Health Canada Implements ICH Q12 and Q14 Guidance

Health Canada has announced the implementation of International Council for Harmonisation (ICH) Q12 and Q14 guidance. The initial scope focuses on Post Approval Change Management Protocols (PACMPs) for Biologic and Radiopharmaceutical Drugs Directorate products, with further implementation details to follow.

Health Product Shortages in Canada: 2024-2025 Review

Health Canada has released its review of health product shortages for the 2024-2025 fiscal year. The report details drug and medical device shortages, including reporting requirements for manufacturers and highlights of high-impact cases. It notes a decrease in new drug shortage reports compared to the previous year.

Health Canada Proposes Reliance on Foreign Drug Authority Decisions

Health Canada is proposing a new Ministerial Reliance Order (MRO) that would allow the Minister to examine new drug submissions by relying on decisions from foreign regulatory authorities. This initiative is part of a broader Red Tape Review aimed at facilitating earlier drug availability in Canada while maintaining safety and quality standards. A 70-day consultation period is currently underway.

Canada Beneficial Ownership Requirements Guidance

FINTRAC has released a video explaining beneficial ownership requirements in Canada, crucial for combating money laundering and terrorist financing. The guidance is relevant to all reporting entities except title insurers.

FINTRAC Imposes $148,912 Penalty on Century 21 Heritage Group Ltd

FINTRAC has imposed an administrative monetary penalty of $148,912.50 on Century 21 Heritage Group Ltd. for failing to submit a suspicious transaction report. This action highlights the agency's commitment to enforcing anti-money laundering and anti-terrorist financing regulations.

FINTRAC Imposes Penalty on Manor Windsor Realty Ltd.

FINTRAC has imposed an administrative monetary penalty of $107,250 on Manor Windsor Realty Ltd. The real estate brokerage was found to be non-compliant with several provisions of the Proceeds of Crime (Money Laundering) and Terrorist Financing Act.

FINTRAC Advisory on Financial Transactions with FATF High-Risk Countries

FINTRAC has issued an advisory regarding financial transactions with countries identified by the Financial Action Task Force (FATF). Reporting entities must treat transactions with the Democratic People's Republic of Korea (DPRK), Iran, and Myanmar as high-risk and apply enhanced due diligence measures.